Do Disease-Modifying Medications Improve Lipid Levels in Heart Disease?
An RCT finds triple therapy with a statin, SGLT2 inhibitor, and PCSK9 inhibitor lowers lipids more than monotherapy in ischemic heart disease. PICO summary and commentary.
Lipids & Statins
Does Semaglutide Improve Lipid Profiles in Type 2 Diabetes?
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
Do Mixed Nuts Improve Cholesterol in Older Overweight Adults?
A randomised crossover trial found 60 g/day of mixed nuts for 16 weeks lowered apolipoprotein B and VLDL and LDL particle numbers in older adults with overweight or obesity. PICO summary and expert commentary.
Tafolecimab in Chinese Patients With Type 2 Diabetes and Hypercholesterolemia: A Post-Hoc Pooled Phase 3 Analysis
A post-hoc pooled analysis of three phase 3 trials testing tafolecimab 450 mg every four weeks for LDL-C lowering in Chinese adults with type 2 diabetes and hypercholesterolemia. PICO summary and expert commentary.
Does Evolocumab Improve Heart Health in Type 1 Diabetes?
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
Does the Omentin-1 Val109Asp Gene Modify Vitamin D’s Metabolic Effects in Prediabetic Women?
A double-blind RCT testing whether the Omentin-1 Val109Asp genotype modifies vitamin D's effects on HDL-C, insulin resistance and abdominal obesity in prediabetic women. PICO summary and expert commentary.
Can HDL-C and Visceral Fat Predict Fat Loss After Sleeve Gastrectomy?
A prediction-model study finds a nomogram of preoperative HDL-C and visceral fat forecasts visceral fat loss after sleeve gastrectomy (AUC 0.88). PICO summary and commentary.
